Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts

✍ Scribed by Praveen Sivakumaran; Ashley A. Vo; Rafael Villicana; Alice Peng; Stanley C. Jordan; Samuel H. Pepkowitz; Ellen B. Klapper

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 101 KB
• Volume: 24
• Category: Article
• ISSN: 0733-2459
• DOI: 10.1002/jca.20206

✦ Synopsis

Abstract

Background: Although there have been desensitization protocols used for ABO‐incompatible (ABOi) renal transplants, there are a lack of studied protocols. Our center developed a preconditioning protocol that involved mycophenolic acid, therapeutic plasma exchange (TPE), anti‐CD20 monoclonal antibody (rituximab), and intravenous immunoglobulin (IVIG) that allowed for ABOi renal transplantation. Methods: Ten patients in our institution with end‐stage renal disease who were unable to procure ABO‐compatible donor kidneys underwent treatment with this protocol (which included a uniform 5 TPE sessions) prior to an ABOi renal transplant. A retrospective chart review was performed on these patients and clinical endpoints including ABO antibody titers, serum creatinine, clinical complications, and graft performance were analyzed. Results: The median ABO antibody titers at presentation, after completion of the protocol, and after transplant for the patients were 32 (range, 2–128), 8 (range, 1–64), and 4 (range, 2–32), respectively. The mean serum creatinine at study conclusion was 1.45 ± 1.04 mg/dl at an average of 262.20 days from transplant. There were four incidents of antibody‐mediated rejection (AMR) and two incidents of delayed graft function (DGF). There was one incident of graft failure and no patient deaths. Conclusions: The desensitization protocol used by our institution allowed for successful ABOi renal transplantation. Although there were incidents of AMR and DGF, the majority of the transplants resulted in viable grafts. A larger patient study group may be needed to fully evaluate the efficacy and safety of this protocol. J. Clin. Apheresis, 2009. © 2009 Wiley‐Liss, Inc.